Cybin (NYSE American: CYBN) (NEO: CYBN) is a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions. The company is on the leading edge of a transformation that has seen the status of psilocybin evolve as a result of mounting public acceptance and growing evidence that the substance delivers remarkable health benefits. “After a flurry of research in the 1950s and 1960s, psilocybin and all other psychedelics were abruptly banned, partly in response to their embrace by the counterculture. Following the 1971 United Nations Convention on Psychotropic Substances, psilocybin was classed in the U.S. as a Schedule I substance… David Nutt, a neuropsychopharmacologist at Imperial College London, is quoted as saying: ‘It’s the worst censorship of research in history.’ This ‘censorship’ appears to be coming to an end as Nutt and others are leading a ‘research resurgence’…,” reads a recent article, which contains excerpts from a Scientific America report. “Cybin is heavily involved in this resurgence of research. The company is leading the industry in developing proprietary psychedelic-based therapeutics, with a pipeline featuring three psychedelic molecules – CYB003, CYB004 and CYB005 – that are delivered from CYBN’s novel drug-discovery platform.”
To view the full article, visit https://ibn.fm/1AYDe
About Cybin Inc.
Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.